The Journal Of Clinical And Aesthetic Dermatology[JOURNAL]
Sun
200 papers
Long-Term Effects of Tear Trough Hyaluronic Acid Filler: A Retrospective Study.
Puyana C, Montes JR
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446717
OBJECTIVE: This retrospective study aims to assess the extended efficacy of tear trough hyaluronic acid (TT-HA) filler treatments beyond the commonly reported duration of 6 to 12 months. METHODS: A retrospective analysis...
OBJECTIVE: This retrospective study aims to assess the extended efficacy of tear trough hyaluronic acid (TT-HA) filler treatments beyond the commonly reported duration of 6 to 12 months. METHODS: A retrospective analysis of 155 patients who received TT-HA filler treatments from 2007 to 2023 was conducted. Patient records and photographs were reviewed, and the severity of infraorbital hollowing was graded using the Merz Infraorbital Hollow Assessment Scale (MIHAS). Multivariate regression models were used to analyze factors influencing treatment longevity. RESULTS: Most patients were female (84%) with a mean age of 48 years. Moderate-to-severe infraorbital hollowing was most prevalent at baseline. On average, 0.45mL of filler was injected into each infraorbital hollow using a 27 gauge x 1-inch cannula. Various HA filler products were used, including Belotero Balance®, Juvederm Vollure® XC, Restylane®, and Juvederm Volbella® XC. Most patients experienced an improvement in MIHAS grade posttreatment, with significant results persisting at 18 months. Multivariate regression analysis revealed sustained efficacy over time, with no significant differences in MIHAS grade changes between 6, 12, and 18-month follow-up periods. CONCLUSION: This study challenges conventional beliefs by demonstrating the extended efficacy of TT-HA fillers, providing evidence of significant improvement in infraorbital hollowing up to 18 months posttreatment. These findings offer valuable insights for clinicians and patients, guiding expectations, and treatment planning in cosmetic dermatology practice. Further research is warranted to elucidate factors contributing to the prolonged longevity of TT-HA fillers to optimize treatment outcomes.
Reaching for the Stars in Atopic Dermatitis: Efficacy, Safety, Tolerability, Accessibility, and Remission/Remittive Effects (ESTAR).
An M, Lio P
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446716
Atopic dermatitis (AD), a chronic inflammatory skin condition affecting up to 20% of children and 7% of adults in the United States, significantly impacts quality of life through recurrent flares and persistent symptoms....
Atopic dermatitis (AD), a chronic inflammatory skin condition affecting up to 20% of children and 7% of adults in the United States, significantly impacts quality of life through recurrent flares and persistent symptoms. This commentary introduces the ESTAR framework-Efficacy, Safety, Tolerability, Accessibility, and Remission/Remittive Effects-as a modernized tool for shared decision-making in AD management. By addressing critical factors such as efficacy (onset speed, depth, durability, and reliability), safety, tolerability, and remission potential, this framework can aid in evaluating emerging therapies with a patient-centered approach. The ESTAR framework emphasizes balancing immediate symptom relief with sustainable long-term disease control, offering tools such as a radar chart to help clinicians and patients navigate complex treatment options, improve adherence, and optimize outcomes in AD care.
Development of a Novel Facial Age Assessment Model in a Multiethnic Population for Evaluation of Topical Anti-Aging Products.
DiCanio D, Lain ET, Del Rosso J … +6 more , Yovine E, Kerns H, Bruning E, Fennessy C, Ouyang H, Saliou C
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446715
OBJECTIVE: The aim of this study was to develop a novel validated computational algorithm for calculating facial age based on the key universal parameters of the face and eyes that contribute to facial aging in women, in...
OBJECTIVE: The aim of this study was to develop a novel validated computational algorithm for calculating facial age based on the key universal parameters of the face and eyes that contribute to facial aging in women, independent of ethnicity and Fitzpatrick skin type. METHODS: Digital facial images of women (n=2825) of 4 different ethnicities, across all Fitzpatrick skin types (I-VI), were evaluated and scored on 15 facial aging markers using a 0 to 10 photonumeric scale (0=no sign of aging; 10=severe signs of aging). Least squares linear multiple regression analysis was performed to identify parameters that contribute independently to observable skin aging and to develop a mathematical algorithm to calculate facial age based on these parameters. RESULTS: The identified key universal parameters contributing to facial age, independent of ethnicity or skin type, were nasolabial folds, under eye lines, elongated cheek pores, forehead lines, under eye puffiness, uneven skin tone, and marionettes, which explained 71% of the variation in age. All parameters increased with age but at different rates, with forehead and marionette lines showing the largest changes with each progressive decade. CONCLUSION: The algorithm developed for calculating facial age based on visual assessments of 7 identified key parameters may be an objective method to evaluate the efficacy of topical anti-aging products.
Skin Injuries Following Layperson Application of Chemical Peel Products.
Lardieri A, Reyes M, Konkel KE … +2 more , Diak IL, McCulley L
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446714
OBJECTIVE: We sought to characterize skin injuries following layperson application of chemical peel products (CPPs). METHODS: Cases of skin injuries following layperson application of CPPs from August 31, 2018 through Au...
OBJECTIVE: We sought to characterize skin injuries following layperson application of chemical peel products (CPPs). METHODS: Cases of skin injuries following layperson application of CPPs from August 31, 2018 through August 31, 2023 were retrieved from the United States Food and Drug Administration (FDA) Adverse Event Reporting System, the Human Foods Complaint System, the literature, and Amazon.com consumer product reviews with images. RESULTS: We identified 18 skin injuries following layperson application of CPPs, including several cases using products labeled with concentrations typically used by healthcare professionals. Injuries involved burns with associated wounds, pain, swelling, and scars. Consequences included disfiguring scarring, reduced mobility, and need for emergency department, dermatologic, or surgical care. Analysis of Amazon.com demonstrated that CPPs are sold under many names with numerous therapeutic claims, list a variety of concentrated agents, and have thousands of reviews. LIMITATIONS: Limitations include underreporting of adverse events to the FDA and incomplete clinical information. With consumer product reviews, there was potential bias and poor replicability due to the dynamic nature of the Amazon website. CONCLUSION: Laypersons who apply CPPs of any strength without guidance from licensed and trained healthcare professionals may experience skin injury and long-term sequelae. Dermatologists are positioned to advise against application of CPPs without professional supervision.
Complications of Topical Timolol in the Management of Infantile Hemangiomas: A Systematic Review.
Werpachowski N, Susla L, Lal K
J Clin Aesthet Dermatol · 2025 Nov · PMID 41446713
OBJECTIVE: Infantile hemangioma (IH) is the most common benign childhood tumor. Timolol is a widely used treatment for IH due to its efficacy and safety. Although systemic absorption is rare, timolol has been detected in...
OBJECTIVE: Infantile hemangioma (IH) is the most common benign childhood tumor. Timolol is a widely used treatment for IH due to its efficacy and safety. Although systemic absorption is rare, timolol has been detected in urine and blood, raising concerns about potential adverse effects. This study aims to systematically review the literature on reported adverse effects associated with topical timolol for IH treatment. METHODS: A systematic review following 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted. PubMed and MEDLINE databases (2000-2024) were searched. Studies reporting treatment-related adverse effects of topical timolol for IH treatment were included. RESULTS: Twenty articles met inclusion criteria, comprising 1780 patients. Local adverse effects occurred in 4.7% of patients, including irritation, scaling, ulceration, and pruritus. Systemic adverse effects occurred in 1.2% of cases, including bradycardia, bronchospasm, wheezing, hypothermia, and sleep disturbances. There was no evidence that the severity or frequency of local adverse effects predisposed patients to systemic ones. Similarly, there was no pattern to suggest that longer treatment durations were associated with increased systemic effects. LIMITATIONS: Limitations include heterogeneity of included studies and the exclusion of studies that did not report complications, which may overestimate the frequencies of local and systemic adverse effects. CONCLUSION: Topical timolol is generally well tolerated for IH treatment, with systemic adverse effects occurring infrequently. Preterm infants and those with ulcerated or deep IHs may be at increased risk for complications. Further research is warranted to better define risk factors for systemic absorption and establish optimal dosing guidelines for safe use in infants.
Remission of Alopecia Areata Post-colectomy in a Patient with Crohn's Disease.
Sulich-Moore C, Altman D
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416239
Alopecia areata (AA) is an immune-mediated, nonscarring hair loss with established associations with various autoimmune conditions, including inflammatory bowel disease. The following case describes a 38-year-old White m...
Alopecia areata (AA) is an immune-mediated, nonscarring hair loss with established associations with various autoimmune conditions, including inflammatory bowel disease. The following case describes a 38-year-old White male patient with Crohn's disease who developed rapidly-progressive alopecia areata during treatment with infliximab. Despite discontinuation of infliximab and aggressive treatment with corticosteroids and tofacitinib, the patient progressed to alopecia universalis within six months. Concurrently, the patient's Crohn's disease required escalation to colectomy with ostomy placement due to inadequate response to vedolizumab. Following his colectomy, the patient continued treatment with tofacitinib and demonstrated dramatic improvement in his AA, achieving complete hair regrowth within one year and maintaining remission two years after discontinuation of all immunosuppressive therapies. This case illustrates potential mechanistic connections between alopecia areata and Crohn's disease through shared inflammatory pathways involving interferon-γ and JAK signaling. The temporal relationship between the patient's colectomy and remission of his alopecia areata suggests a gut-immune axis mechanism, where addressing the primary intestinal inflammatory source may have influenced a remote autoimmune manifestation. This case highlights the potential for targeting primary inflammatory sources to achieve broader immunologic benefits in patients with concurrent autoimmune conditions.
What Are Topical Adaptogens? A Systematic Review and Proposed System to Identify and Categorize Skin Adaptogens in Dermatology.
Blyumin-Karasik M, Colon J, Karasik D … +3 more , Nguyen S, Woolery-Lloyd H, Lain E
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416238
BACKGROUND: Skin adaptogens are a class of active ingredients that can enhance human adaptation by reducing the deleterious effects of intrinsic and extrinsic stressors. Adaptogens' homeostatic actions enhance the skin's...
BACKGROUND: Skin adaptogens are a class of active ingredients that can enhance human adaptation by reducing the deleterious effects of intrinsic and extrinsic stressors. Adaptogens' homeostatic actions enhance the skin's resilience, improving skin health and quality. Most of the investigated and identified adaptogens are botanicals and have relevant applications in dermatology, but their precise mechanism of action (MOA) and classification are yet to be determined. METHODS: Articles related to botanical adaptogens published within the last 20 years were obtained from the Ovid, Cochrane, and PubMed databases. Studies had to include botanicals studied topically on the skin and classified as adaptogens in the paper. The systematic search resulted in 643 articles, and after the selection process, 12 studies were chosen for the systematic review. RESULTS: Twelve scientific papers identified 29 topical adaptogens with capabilities of promoting skin health and cosmesis via homeostatic mechanisms. These papers reviewed the effects of topical adaptogens on photodamage, photoaging, antioxidant activity, antimicrobial activity, inflammation, metabolic activity, hormones, and regenerative effects. We propose an identification and classification system of topical adaptogens. We also list currently identified topical adaptogens in the literature and propose other potential cutaneous adaptogens. CONCLUSION: We have identified 29 skin adaptogens and categorized them based on their MOA: safe, homeostatic, and multitargeted. We propose this classification system as a guide to identify and catalog topical adaptogens in dermatology.
Assocation of Psoriasis and Occupational Organic Dust Exposure: A Cross-sectional Analysis of NHANES 2009-2012 Data Among US Adults.
Osborne S, Kam O, Vo C … +3 more , Wescott R, Thacker S, Wu J
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416237
OBJECTIVE: The goal of this study was to examine the relationship between psoriasis and occupational organic dust exposure among United States (US) adults 20 to 79 years of age. METHODS: We merged two, two-year cycles (2...
OBJECTIVE: The goal of this study was to examine the relationship between psoriasis and occupational organic dust exposure among United States (US) adults 20 to 79 years of age. METHODS: We merged two, two-year cycles (2009 to 2010 and 2011 to 2012) of data from the National Health and Nutrition Examination Survey (NHANES). Of 10,990 participants, 483 were excluded due to incomplete data, resulting in a cohort of 10,507 individuals. We utilized STATA/SE 18.0 for multivariable logistic regression analyses. RESULTS: Among individuals with psoriasis, the prevalence of organic dust exposure was 32 percent compared to 22 percent with organic dust exposure among those without psoriasis. There was a significant association between psoriasis and organic dust exposure among patients ages 20 to 79 years after adjusting for potential confounding variables (adjusted odds ratio [AOR]: 1.68; 95% confidence interval [CI]: 1.19-2.36; =0.004). There was significant organic dust exposure among female participants with psoriasis (=0.040), and increased rates of exposure among adults with psoriasis ages 40 to 59 years (=0.038) and adults with psoriasis ages 60 to 79 years (=0.034). There was a higher percentage of psoriasis participants with over fifteen years of organic dust exposure (43%) compared to those without psoriasis (23%) (=0.038). LIMITATIONS: Limitations include the possibility of recall bias due to self-reporting and inability to control for psoriasis severity. CONCLUSION: Organic dust exposure was significantly associated with psoriasis in this study. These results remained significant when examining female subgroups, ages 40 to 59 years, and ages 60 to 79 years. There was also a statistically significant presence of psoriasis among individuals with occupational organic dust exposure of fifteen years or more.
Successful Treatment of Confluent and Reticulated Papillomatosis With Calcipotriene and Tretinoin: A Novel Topical Regimen.
Nathoo R, Siddiqui F
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416236
Confluent and reticulated papillomatosis (CARP) is a rare dermatosis of uncertain etiology characterized by scaly, hyperpigmented papules that coalesce into reticulated plaques, typically affecting the upper trunk of ado...
Confluent and reticulated papillomatosis (CARP) is a rare dermatosis of uncertain etiology characterized by scaly, hyperpigmented papules that coalesce into reticulated plaques, typically affecting the upper trunk of adolescents and young adults. While oral minocycline remains the most established treatment, relapse and adverse effects often are limiting factors. We present the case of a 25-year-old male patient with an 18-month history of CARP who experienced initial improvement with oral antibiotics but discontinued systemic therapy due to side effects. The patient was successfully treated with a novel topical regimen of calcipotriene 0.005% cream daily and tretinoin 0.05% cream nightly, achieving complete clearance after 3 months of consistent use without adverse effects. This case supports the role of disordered keratinization in CARP and demonstrates that topical calcipotriene and tretinoin may offer a safe and effective treatment alternative for patients who cannot tolerate or prefer to avoid systemic antibiotics.
Updates from the AAD and AAAAI Guidelines for Managing Atopic Dermatitis.
Sodha D, Patel A, Lio P
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416235
INTRODUCTION: In 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology Joint Task Force (JTF) updated their guidelines for management of atopic dermatit...
INTRODUCTION: In 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI)/American College of Allergy, Asthma, and Immunology Joint Task Force (JTF) updated their guidelines for management of atopic dermatitis from their last update in 2012. The American Academy of Dermatology (AAD) also updated their own guidelines from 2014 for the diagnosis, assessment, safety, and efficacy of treatments in 2024. In this review, we outline the key changes from the prior guidelines and highlight the major differences between the two recommendations. RESULTS: The majority of the guidelines and recommendations are similar in their overall recommendations with small stylistic differences including application frequency and combination of therapies. Key differences between the two recommendations include topical PDE-4 Inhibitors, topical JAK Inhibitors, systemic JAK inhibitors, azathioprine, methotrexate, and mycophenolate. The final difference between the AAD and JTF guidelines is that AAD categorizes evidence and comments on the certainty of association for each group of comorbidities, while JTF makes general statements regarding comorbidities.
Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-Q.
Romanelli S, Ball GD, Hamade H … +5 more , Taliercio M, Levy Z, Perez-Chada L, Merola JF, Gottlieb AB
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416234
OBJECTIVE: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with systemic inflammation and reports of increased prevalence and risk of inflammatory arthritis. Despite this, there is a lack...
OBJECTIVE: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with systemic inflammation and reports of increased prevalence and risk of inflammatory arthritis. Despite this, there is a lack of tools to assess musculoskeletal (MSK) symptoms in patients with HS. This quality improvement initiative aims to evaluate MSK symptom severity and impact in patients with HS using the International Dermatology Outcome Measures (IDEOM) Musculoskeletal Questionnaire (MSK-Q). METHODS: Over 20 months, the IDEOM MSK-Q was distributed to 115 patients with HS receiving care at a single dermatology clinic. Demographic and clinical data were collected at all visits. The IDEOM MSK-Q is a 9-item tool scored on a 10-point scale, with subscores evaluating MSK symptom severity, impact on quality of life, and fatigue in the past week. RESULTS: At baseline, 79.14 percent of patients reported joint symptoms, with 33.91 percent rating joint pain ≥7/10. Fatigue was also prevalent (47.82% rating ≥7/10). Higher HS severity was significantly correlated with greater MSK symptom burden, with the greatest impact reported in work and/or school activities and daily physical activities. Follow-up assessments suggested symptom improvement with systemic treatment, though statistical significance was not achieved. LIMITATIONS: This study has a small sample size and limited follow-up duration. CONCLUSION: Our analysis shows substantial MSK symptom burden and fatigue among patients with HS. The IDEOM MSK-Q may be a valuable tool for assessing MSK symptoms and impact, supporting further development and validation in the HS population.
Systematic Review of the Efficacy and Safety of Topical Glutathione in Dermatology.
Khanna R, Rambhia P, Chapas A
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416233
BACKGROUND: Glutathione, a potent antioxidant, has gained attention for its skin-lightening effects, leading to ethical debates. Social media influence has popularized its use in various skincare products such as under-e...
BACKGROUND: Glutathione, a potent antioxidant, has gained attention for its skin-lightening effects, leading to ethical debates. Social media influence has popularized its use in various skincare products such as under-eye creams, face masks, sunscreens, and moisturizers. Despite its popularity, scientific research on topical glutathione is limited. OBJECTIVE: To perform a review of existing literature on the safety and efficacy of topical glutathione. METHODS: A PRISMA-guided systematic review was conducted using PubMed and MEDLINE databases with search terms "glutathione" AND "topical" AND "skin" OR "dermatology." From 446 articles, only clinical trials on topical glutathione were included, excluding reviews, animal studies, and research on oral or intravenous glutathione. Five clinical trials met the inclusion criteria. RESULTS: Studies suggest glutathione may improve hyperpigmentation and provide antioxidant advantages. A glutathione amino acid precursor (GAP) blend increased the glutathione reduced monomers (GSH) oxidized dimers glutathione disulfide (GSSG) ratio, a surrogate measure for oxidative damage repair capacity. S-acyl glutathione 2% cream significantly reduced ultraviolet-induced erythema (=0.0003). A 2% oxidized glutathione lotion decreased the melanin index (<0.05), total epidermal water loss (TEWL) (<0.05), and wrinkles (<0.01). Combination creams with glutathione also showed benefits, though tolerability was varied. Safety data is limited and warrants further exploration. CONCLUSION: Topical glutathione shows promise for dermatological applications. Further randomized controlled trials are necessary to fully evaluate its efficacy in hyperpigmentation, TEWL, skin elasticity, and ultraviolet (UV) damage. Additionally, ethical considerations regarding its use as a skin-bleaching agent must be addressed to avoid reinforcing structural racism and healthcare disparities.
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% to Treat Acne Induced by Janus Kinase Inhibitor Treatment: A Case Report.
Olszewski N, Bunick CG
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416232
Janus kinase inhibitors (JAKi)-developed to treat inflammatory and immune-mediated diseases-have shown an increased risk of acne development, especially when used to treat dermatologic conditions. There are no treatment...
Janus kinase inhibitors (JAKi)-developed to treat inflammatory and immune-mediated diseases-have shown an increased risk of acne development, especially when used to treat dermatologic conditions. There are no treatment guidelines for JAKi-induced acne. Some of the most efficacious treatments for acne vulgaris (AV) are triple combinations, including benzoyl peroxide (BPO), a topical retinoid, and an oral/topical antibiotic. Fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel has demonstrated good efficacy, safety, and tolerability in Phase 2 and 3 clinical trials of participants with moderate to severe AV. This case report highlights the possible utility of once-daily CAB for JAKi-induced acne. A 15-year-old female patient was administered the oral JAKi upadacitinib (15mg daily) for 16 weeks to treat atopic dermatitis that inadequately responded to dupilumab. The patient had mild preexisting comedonal and inflammatory facial AV prior to JAKi treatment. Over the first few months of JAKi treatment, her acne worsened to moderate/severe inflammatory acne, with erythema and postinflammatory hyperpigmentation. The patient applied CAB gel to the face once daily for approximately 20 weeks with substantial acne improvement and without adverse effects. CAB treatment reduced her acne severity to mild to almost clear, and no significant acne-induced sequelae (scarring, postinflammatory hyperpigmentation, or erythema) were observed. She continues treatment with both CAB and upadacitinib. Treatment guidelines for AV often recommend oral drugs, such as isotretinoin, for moderate-to-severe acne. This case presented here, however, demonstrates that topical CAB gel can treat moderate to severe JAKi-induced inflammatory acne.
Economic and Clinical Value Delivered by Dermatology Trainees From 2016 to 2023.
Zhou AE, Gronbeck C, Sloan B … +1 more , Feng H
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416231
Abstract loading — click title to view on PubMed.
Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series.
Dasilva DR, Soto-González A, Mollanazar NK … +9 more , Ndubisi S, Issa N, Song JE, Shahriari M, Bunick CG, Lio P, Nguyen HP, Yosipovitch G, Del Rosso J
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416230
OBJECTIVE: Chronic pruritus significantly impacts quality of life and remains challenging to manage, particularly in patients unresponsive to systemic therapies. Nemolizumab, a monoclonal antibody targeting the interleuk...
OBJECTIVE: Chronic pruritus significantly impacts quality of life and remains challenging to manage, particularly in patients unresponsive to systemic therapies. Nemolizumab, a monoclonal antibody targeting the interleukin (IL)-31 receptor, has shown promise in alleviating pruritus across several dermatologic conditions. However, data on its efficacy in treatment-resistant cases, particularly in real-world settings, remain limited. This case series evaluates the efficacy and safety of nemolizumab in patients with treatment-resistant chronic pruritus. METHODS: A multicenter retrospective review was conducted across private dermatology practices and large academic dermatology centers. Patient records were reviewed for demographics, comorbidities, treatment history, and clinical outcomes, including Body Surface Area (BSA), Investigator Global Assessment (IGA), and Peak Pruritus Numerical Rating Scale (PP-NRS). Adverse events were recorded. RESULTS: Twelve patients (5 with atopic dermatitis, 2 with prurigo nodularis, 3 with chronic pruritus of unknown origin, and 2 with concomitant atopic dermatitis and prurigo nodularis) were included. All had previously failed systemic therapies. Mean baseline BSA was 45 percent (range 5-88%), with mean PP-NRS of 9 (range 6-10). After treatment, mean BSA and PP-NRS decreased to 4 percent (11-fold reduction) and 0.9 (10-fold reduction), respectively. Most (10/12) experienced significant pruritus relief within 24 to 72 hours of nemolizumab initiation. No serious adverse events were noted, including in patients with a history of malignancy or end-stage renal disease. LIMITATIONS: Small sample size, retrospective design, limited follow-up, and absence of a control group. CONCLUSION: Nemolizumab demonstrated rapid and substantial efficacy in treatment-resistant chronic pruritus with a favorable safety profile, even in patients with significant comorbidities.
Availability of Hats Online in the United States that Meet Sun Protective Recommendations.
Gyongyosi N, Constanza J, Ilyas EN
J Clin Aesthet Dermatol · 2025 Sep · PMID 41416229
OBJECTIVE: The objective of this study is to determine the likelihood for online consumers seeking hats for sun protection in the United States (US) successfully finding one that meets the recommended criteria for adequa...
OBJECTIVE: The objective of this study is to determine the likelihood for online consumers seeking hats for sun protection in the United States (US) successfully finding one that meets the recommended criteria for adequate UV protection and whether UPF claims made by these products are reliable indicators of this protection based on materials, structure, and design. METHODS: Online US consumer experience was simulated to identify the top 20 hats targeting consumers seeking sun protection. Specific details were evaluated for the top 20 products identified based on the volume of product occurrences identified as key markers for ultraviolet (UV) protection including the hat style, brim length, UPF claims, presence of ventilation eyelets or mesh, and presence of a reflective undersurface. RESULTS: Although 90 percent of hats marketed for use in the sun made UPF claims, there was a 60 percent probability of finding a hat that conformed to stringent UPF standards for hats set forth by UK and Australian testing standards for UPF claims to be made by hats to be used for sun protection factoring in materials, structure, and design. CONCLUSION: Given the lack of conformity for UPF testing and 33 percent of hats failing to meet criteria for adequate sun protection based on materials, structure, and design, UPF claims for hats sold in the US online are not a reliable indicator for sun protection. Recommendations for hats for UV protection should focus on crown coverage, circumferential brim with length of at least 2.75", materials with minimal disruption, and not UPF claims.
Efficacy of a 2-MNG-Containing Serum and Sunscreen Regimen on Improving Facial Dyschromia in Women with Skin of Color.
Dumbuya H, Alexis A, Lynch S … +3 more , Callender V, Desai SR, Draelos ZD
J Clin Aesthet Dermatol · 2025 Oct · PMID 41416032
OBJECTIVE: Populations with skin of color remain under-represented in dermatology clinical trials. Here, we first evaluated the efficacy of a serum and sunscreen regimen, containing 2-mercaptonicotinoyl glycine (2-MNG, M...
OBJECTIVE: Populations with skin of color remain under-represented in dermatology clinical trials. Here, we first evaluated the efficacy of a serum and sunscreen regimen, containing 2-mercaptonicotinoyl glycine (2-MNG, Melasyl), a new ingredient that quenches melanin precursors, on improving facial dyschromia in women with skin of color. METHODS: This open-label study completed with 60 female participants, aged 25-70 years old, from diverse racial/ethnic backgrounds with skin phototypes IV-VI and presenting with mild to moderate hyperpigmentation and skin roughness. After completing a 1-week washout period, all participants used a 2-MNG-containing serum and sunscreen SPF30 regimen for 12 weeks. Evaluations included clinical assessments, quality of life questionnaires, plus imaging at several time points. RESULTS: After 2 weeks of treatment, dermatological assessments showed significant improvement in skin brightness and radiance in all participants. At Week 4, we observed significant reduction in dyschromia and hyperpigmentation. Expert grading and clinical imaging also demonstrated significant improvement in skin smoothness and pores appearances. By Week 12, all participants perceived a significant improvement in quality of life: from feeling less unattractive to decreasing the use of camouflage to cover up skin concerns. Lastly, skincare regimen was overall well tolerated by all participants. LIMITATIONS: This study evaluated the 2-MNG containing skincare regimen efficacy and did not specifically address the effectiveness of individual ingredients, nor include a comparison to a gold standard treatment. CONCLUSION: Overall, our results demonstrate that a 2-MNG-containing serum and sunscreen SPF30 regimen effectively reduces the appearance of facial dyschromia, while improving skin texture and quality of life among women with skin of color.
A 7-Week, Open-Label Study Evaluating the Efficacy and Safety of 415-nm/633-nm Phototherapy for Treating Mild-to-Moderate Acne in Adolescents and Adults.
Ablon G
J Clin Aesthet Dermatol · 2025 Oct · PMID 41416031
OBJECTIVE: Acne vulgaris is a major health and social concern for many adolescents and adults. The goal of this study was to further assess the efficacy and safety of a United States Food and Drug Administration cleared...
OBJECTIVE: Acne vulgaris is a major health and social concern for many adolescents and adults. The goal of this study was to further assess the efficacy and safety of a United States Food and Drug Administration cleared light-emitting diode (LED) therapy (Omnilux Clear, GlobalMed Technologies) for treating adolescents and adults with mild-to-moderate facial acne. The device is a wearable facial mask designed for home use that simultaneously emits light in red (633 nm) and blue (415 nm) wavelengths. METHODS: The study enrolled male (n=15) and female (n=15) patients aged 14 to 45 years old. Patients were required to have an Investigators Global Assessment (IGA) score of 2 (mild) or 3 (moderate). Patients applied the treatment at home 4 times weekly, never more than once daily, and allowed 24 hours between treatments. The primary efficacy endpoints were the change from baseline in inflammatory and noninflammatory lesion counts, and the proportion of patients achieving a ≥1-grade reduction in IGA scores from baseline. Other assessments included quality of life and tolerability questionnaires. RESULTS: After 7 weeks, there were significant reductions in inflammatory and noninflammatory lesion counts (for each, <0.0001) and most patients (86%) achieved ≥1-grade reduction in IGA scores, meeting study success criteria. The few reported adverse events were mild and transient. LIMITATIONS: The primary limitation of this study was the open-label study design. CONCLUSION: These results provide strong support for this wearable LED device for the safe and effective home treatment of adolescents and adults with mild-to-moderate acne.
Enhancing Diagnostic Precision in Primary Care: A Multireader Multicase (MRMC) Study of an AI-Powered Handheld Elastic Scattering Spectroscopy Device for Informed Referral Decisions in Melanoma Evaluation.
Seiverling EV, Shah A, Weinstock MA … +3 more , Grant-Kels JM, Falk NP, Siegel DM
J Clin Aesthet Dermatol · 2025 Oct · PMID 41416030
BACKGROUND: Skin cancer is the most common cancer faced by adults in the United States. Melanoma, while a less common subtype of skin cancer compared to basal cell and squamous cell carcinomas, is associated with greater...
BACKGROUND: Skin cancer is the most common cancer faced by adults in the United States. Melanoma, while a less common subtype of skin cancer compared to basal cell and squamous cell carcinomas, is associated with greater rates of metastases, mortality, and morbidity, and its rate of incidence is projected to increase. Primary care physicians (PCPs) can play an important role in skin cancer detection and in the decision to refer a patient to a dermatologist. Technologies such as the elastic scattering spectroscopy (ESS) device (DermaSensor, Inc.), a handheld, noninvasive assistive tool, may help in the evaluation of a skin growth and improve appropriate referral decision making. METHODS: A total of 50 malignant and 50 benign lesions were assessed by each of the 118 physicians (board-certified internal and family medicine physicians), yielding 5,900 malignant and benign lesion assessments without the device and 5,900 with the ESS device. Physicians were also surveyed regarding their confidence in their management decision. RESULTS: The study met the primary endpoint; the area under the receiver operating characteristic (AUROC) of the PCPs aided with the device was 0.671 (95% confidence interval [CI]: 0.611-0.732) compared with the AUROC unaided by the device of 0.630 (95% CI: 0.582-0.678), a significant increase (=0.036). When asked whether the device would provide value to their decision making, 91.5% of respondents either agreed or strongly agreed. CONCLUSION: The ESS device improved PCP accuracy in managing lesions suggestive of melanoma and increased their sensitivity for all skin cancers and melanoma. Participating internal medicine and family medicine physicians reported increased confidence in their assessments with the device. The ESS device can improve PCP decision making when managing lesions suggestive of melanoma.
Improvement of Early Detection of Cutaneous Malignancies and Reduction of Healthcare Costs at Farmers' Markets and a Church in Oklahoma City: A Pilot and Cross-Sectional Study.
Kunadia A, Brito V, Oh J … +4 more , Smith A, Li H, Zhao D, McBride J
J Clin Aesthet Dermatol · 2025 Oct · PMID 41416029
OBJECTIVE: The authors sought to evaluate the feasibility, educational outcomes, and cost-savings of free dermatologic screenings at local farmers' markets and a church in Oklahoma City, Oklahoma. METHODS: We piloted six...
OBJECTIVE: The authors sought to evaluate the feasibility, educational outcomes, and cost-savings of free dermatologic screenings at local farmers' markets and a church in Oklahoma City, Oklahoma. METHODS: We piloted six free skin cancer screenings at farmers' markets and a church in Oklahoma. Exposed areas were examined by dermatology residents under supervision of a board-certified dermatologist. Suspicious lesions were referred. Pre- and postscreening surveys assessed knowledge, sunscreen use, and barriers to care. Demographics and ZIP codes were collected. Follow-up was conducted at 6 months. We estimated cost savings per screening using published visit costs and Internal Revenue Service (IRS) mileage rates. Statistical analysis included paired -tests, analysis of variance (ANOVA), and chi-square tests (<0.05). RESULTS: Among 411 adults, 40 participants (9.7%) had notable lesions, including 7 confirmed basal cell carcinomas and 23 actinic keratoses. Awareness of risk-reducing practices and lesion recognition increased significantly postcounseling (both <0.0001). The most reported barrier to dermatology was lack of perceived need. Estimated cost savings per participant was $156.70, totaling $64,403.70 across all participants. LIMITATIONS: Limitations include reliance on self-reported survey data, incomplete follow-up among referred participants, and lack of histopathologic confirmation for all findings. CONCLUSION: This study shows the feasibility and cost-effectiveness of free skin screenings when paired with local farmers' markets, which often provide complimentary spaces for nonprofit organizations. These low-cost models may enhance earlier detection and awareness in communities with limited access.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe